From patient data to novel targets and biomarkers: UK Biobank use case.
Traditional drug discovery is slow, costly, and often disconnected from the real biology of patients. However, biobank resources like the UK Biobank can help overcome current challenges by delivering access to vast genomic, proteomic, and phenotypic datasets. But the question is: How do we translate millions of patient data points into actionable discoveries?
Join us for this valuable webinar for a deep dive into AI-powered biobank analysis. Learn how it enables the identification of causal pathways, discovery of novel subgroups, and smarter therapeutic decisions. We’ll explore strategies that will allow you to:
Apply AI to large-scale patient data for uncovering hidden phenotypes and subgroups
Leverage biobank insights to drive drug repurposing and indication expansion
Accelerate target identification with proteomics-driven discovery
And more
Don’t miss out on real-world examples that show how AI-based analysis impacts novel discoveries based on patient data. Register today!
Meet our speakers:
Bart Smets, PhD
He leads the Molecular Measures team that is focused on leveraging multi-omics signatures from large patient cohorts and preclinical models to identify new drug targets and to create novel patient stratification tools to enable precision neuroscience. Bart was trained as a bioengineer and bioformatician. He obtained a PhD in Sciences at the Catholic University of Leuven, Belgium. Bart has 15+ years of experience in biotech and pharma.
